ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0007050;cell cycle arrest;6.0;0.811012628672052;0.7286266269261705;9.292052015870908;55.61614271062087;4.7664383335842135;0.0018614222452456451;0.5668761906316916;[ERN1, CDKN1C, CDKN1A, CDKN2C, FAP, TP53INP1, PRR11, THBS1, PRKAB1, EIF4G2, PPM1G]
GO:0006482;protein demethylation;8.0;0.7508913569872202;0.7504456784936101;9.242861771680136;158.66518328064822;6.311337724880743;0.005310380895009016;0.6977621047576203;[UBE2B, PPME1]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[CDKN1C, BECN1, BTG2, CDKN1A, CD80, LST1, SIRPG, CIB1, COMT, THBS1, STK3, FLCN, ADORA3, RPS6KA2, FNTB, NUP62, TP53INP1, LMNA, TRIM24, CSK, RBM5, E2F7, TFAP2A, KLF13, CDKN2C, IGFBP5, ATPIF1, IDH2, GLMN, IFT122, EMP3, PDCD1LG2, SIRT2, PER2, ITCH, SFRP1, TWSG1, IL6, GAL, KARS, FAP, NFIB, CD9, TAX1BP3, MNDA, CNOT8, TRIM32]
GO:0044795;trans-Golgi network to recycling endosome transport;6.0;1.0;0.8231203125901445;9.628524252492122;48.979792040619635;9.777073627680469;0.0016393095606485504;0.8231203125901445;[RAB13]
GO:0006886;intracellular protein transport;8.0;0.5537205960740763;0.6518602980370382;8.117066748418225;90.55259897265384;3.0436717358431102;0.0030307139955665606;0.5306535141162272;[RAB3B, ARF3, TRAM1, AHCYL1, RPL3, NCF1, CLTA, IPO4, RAB43, IPO8, AP1G1, NUP62, LAMP2, TMED2, TMED1, ARFIP1, EVI5L, TNPO1, TNPO2, TBC1D22A, RAB8B, VPS18, GSTK1, GRIPAP1, TMED9, RPS9, SSR2, COG3, TBC1D8, SYTL3, BCR, ACOX2, AGPS, CHMP4B, SLU7, SLC27A2, KPNB1, ACOT4, COPB2, COPA, RABGAP1, ZDHHC23, HSD17B4, ZDHHC24, DERL2, VPS26B, TRAK1, RGPD1, NAPG, STX11, ARNTL, RAB21, AP3M1, RAB20, GGA3, LMNA, VPS11, AP2S1, HEATR3, STX5, BID, RAB6A, RAE1, RPL19, VPS16, PEX16, PEX19, RAB3IP, SYVN1, NUP153, RAB27B, RPL23A, TIMM44, RAB11A, ARCN1, NFKBIA, PAN3, SNX17, VPS41, BCL3, RAB13, RAB18, RAB3GAP2, SEC24C]
GO:0043687;post-translational protein modification;7.0;0.6467165523344657;0.6742776414244334;8.507933057105237;151.15475272427284;3.8799197600437285;0.005059013543235805;0.5493386422205575;[ITIH2, PRKCSH, SERPINA10, CCNF, NEDD8, MSLN, PSMB10, PSMA7, PSMD8, C3, TGOLN2, PSMD7, PSMD4, RBBP5, PSMD2, UBD, PSMB1, SKP2, APOL1, FGA, KLHL25, IGFBP5, FGG, FBXL15, FBXL16, RAB11A, DDB1, IL6, COPS5, PSMA1, PSMC1, RAB13, PSME2, FBXL3]
GO:0030866;cortical actin cytoskeleton organization;6.0;0.7671156992804218;0.7066781622303554;9.117698628726131;53.946853691669205;6.088194173566533;0.0018055526440439148;0.63447084575632;[VIL1, NCKAP1, PDCD6IP, EPB41, ROCK2, WIPF2, RAB13, NCKAP1L]
GO:0032869;cellular response to insulin stimulus;8.0;1.0;0.875;9.628524252492122;462.69925393661634;5.334422371190153;0.015486127626965131;0.6478026081386739;[ERRFI1, SP1, MARS, RAB13, RAB8B]
GO:0072583;clathrin-dependent endocytosis;7.0;0.8436909121759173;0.7727648213451592;9.223059144383958;30.046907922432062;6.558197802812269;0.0010056429677022863;0.6863059058804069;[AP2S1, CLTA, FNBP1L]
GO:0016191;synaptic vesicle uncoating;9.0;1.0;0.896240625180289;9.628524252492122;42.883923758655996;8.16763571524637;0.0014352863351765049;0.8139338954918922;[SYNJ1, SH3GL1]
GO:0031658;negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle;13.0;1.0;0.9625549647676366;9.628524252492122;3330.314475181895;7.8311634786251565;0.11146262839589782;0.8630410292508717;[CDKN2C]
GO:0000086;G2/M transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;43.44612409677276;4.981283082083729;0.0014541026745458175;0.5449840603320351;[CDKN1A, CCNB1, PPME1, CEP70, FBXL15, SKP2, MAPRE1, CKAP5, CLASP1, CDC25A, PAFAH1B1]
GO:0032802;low-density lipoprotein particle receptor catabolic process;7.0;1.0;0.8509193652572005;9.628524252492122;464.4154505485325;7.474488534686424;0.01554356718308929;0.7331650565203278;[AP2S1, CLTA]
GO:0097368;establishment of Sertoli cell barrier;6.0;1.0;0.8231203125901445;9.628524252492122;53.96940310801916;8.16763571524637;0.0018063073527159906;0.7408135829017477;[RAB13, ARID4A]
GO:0030308;negative regulation of cell growth;6.0;0.6913464685778243;0.6687935468790567;8.673012807464685;80.89021177018715;4.623782033182691;0.0027073225914839173;0.5595807407949613;[SEMA6B, PPP2CA, FLCN, SERTAD3, SFRP1, CDKN1A, GAL, CDKN2C, NPPA]
GO:0048268;clathrin coat assembly;6.0;0.8436909121759173;0.7449657686781032;9.310070521373587;44.51706700895919;6.781341354126479;0.0014899461700306506;0.6699184248047958;[AP2S1, CLTA]
GO:0000082;G1/S transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;42.752976916212816;5.142344639450834;0.0014309036622044387;0.5532207558659172;[CDKN1A, CDKN2C, MAX, GMNN, MCM10, CDC25A, POLE4, PPP6C, GPR132, CCNE2, POLE2, SKP2, MCM2]
GO:0010737;protein kinase A signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;7.474488534686424;8.845336528452411E-4;0.7053660038532718;[GAL, RAB13, LCP1]
GO:0098815;modulation of excitatory postsynaptic potential;7.0;0.7866048967936545;0.7442218136540277;9.392135474427892;100.6598909114356;6.139487467954083;0.0033689959607854014;0.6648930398837374;[SH3GL1]
GO:0060071;Wnt signaling pathway, planar cell polarity pathway;9.0;0.7436939687323844;0.7680876095464813;9.094441766561864;99.0414819593438;5.825829909099042;0.0033148292696323837;0.694173837660411;[SFRP1, AP2S1, DVL3]
GO:0030100;regulation of endocytosis;6.0;0.5902001590945054;0.6182203921373972;8.152617732682543;44.90533409728707;4.321752512322768;0.0015029411200592913;0.5441349370523758;[CD151, MCTP1, FCER1G, TOR1A, ITGA2, SIRPG, STON1, C2, RAB21, BCR, RUFY1, C3, ABR, ATXN2, RAB20, SYNJ1, SNX17, AP2S1, PTX3, NCKAP1L, CSK, CCL19, DOCK2, SH3GL1]
GO:0019886;antigen processing and presentation of exogenous peptide antigen via MHC class II;5.0;1.0;0.7902410118609202;9.628524252492122;42.20009821028515;5.192106149009898;0.0014123993094755708;0.5557655617789146;[DCTN5, FCER1G, DCTN4, CLTA, KLC1, DYNLL2, KIF15, CENPE, HLA-DMA, HLA-DMB, AP1G1, HLA-DPB1, AP2S1, KIF2C, CTSE, HLA-DRB3, SEC24C, HLA-DQA1, HLA-DPA1]
GO:0048709;oligodendrocyte differentiation;5.0;0.8933024483968273;0.736892236059334;9.34084218004034;23.145667324477426;6.518977089658987;7.746646556020492E-4;0.623621803389518;[CDKN2C, SOX8, TSPAN2, CSK]
GO:1902463;protein localization to cell leading edge;5.0;1.0;0.7902410118609202;9.628524252492122;29.829169826127035;9.083926447120524;9.983554695705216E-4;0.7547934328124444;[RAB13]
GO:0032482;Rab protein signal transduction;8.0;1.0;0.875;9.628524252492122;29.60642063139588;5.500407508664414;9.9090025448413E-4;0.6562910957882058;[RAB21, RAB3B, RAB43, RAB20, RAB13, RAB18, RAB27B, RAB6A, RAB11A, RAB8B]
GO:1900244;positive regulation of synaptic vesicle endocytosis;8.0;0.9326813400603323;0.8413406700301662;9.577230958104572;265.8961164942356;7.9853141584524145;0.008899303728093307;0.7833693374183408;[TOR1A, SH3GL1]
GO:0006897;endocytosis;5.0;0.6324783794010864;0.6064802015614634;8.088079211544972;26.35802846831835;3.582668236575797;8.821794921490709E-4;0.47345883209051776;[COLEC12, CD163L1, TFRC, WIPF2, ITGB3, ITGB2, STON1, CLTA, FNBP1L, RABEPK, LRP8, TM9SF4, KIAA1109, AP2S1, APOL1, SCARF1, FCER1G, AMBP, FNBP1, UNC13D, MARCH3, RUFY1, SYNJ1, SNX17, CD9, PIK3C3, DOCK2]
GO:0032515;negative regulation of phosphoprotein phosphatase activity;10.0;0.8653626801206646;0.8479223519212526;9.5525383455142;1090.4524045737035;5.788089581116195;0.03649646063763195;0.7112441822128948;[PPP1R11, ROCK2, PPME1, PHACTR2, NCKAP1L]
GO:0048013;ephrin receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;31.002284443533863;5.395046993006588;0.0010376185600805164;0.6509029541176994;[ACTR2, ARPC2, ROCK2, ARPC1A, AP2S1, EPHA1]
GO:0035767;endothelial cell chemotaxis;8.0;0.9326813400603323;0.8413406700301662;9.548481544818586;58.99646552848538;7.474488534686424;0.0019745586078665435;0.7572456912631272;[RAB13]
GO:0070830;bicellular tight junction assembly;6.0;1.0;0.8231203125901445;9.628524252492122;56.140948375987016;6.280566066213989;0.001878987018571015;0.6443087532925187;[PDCD6IP, RAB13, ECT2]
GO:0032456;endocytic recycling;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;48.979792040619635;6.409777797693995;0.0016393095606485504;0.6509166472493662;[RAB13]
GO:0072659;protein localization to plasma membrane;6.0;0.7866048967936545;0.7164227609869718;9.260799472366804;65.42666064804821;4.677207199856271;0.002189771451718415;0.5623129063031725;[BBS2, RAB3B, GRIPAP1, SYS1, FCER1G, ROCK2, ZDHHC23, ABCA12, RAB11A, SLMAP, RAB13, TMED2, VAMP5, RAB8B]
GO:0016567;protein ubiquitination;9.0;0.6913464685778243;0.7419138594692012;8.996001693748612;153.79381005389072;3.300101264790787;0.005147340417060716;0.5650079573320931;[PPP1R11, CCNF, UBE2Z, UBE2L3, TRIM9, NPEPPS, HERC4, HERC1, CDC26, TRIM24, TRIM69, SKP2, C18orf25, FBXO18, DTX3L, ZFP91, TRPC4AP, DDB1, KCTD10, ANAPC5, HIST1H2BC, HIST1H2BO, HIST1H2BJ, CDCA3, RNF38, UBR4, NEDD8, DTX2, KLHL12, NLRC4, ANAPC11, VCPIP1, RNF213, UBD, HLTF, RFFL, RNF20, UBE2I, UBE2B, KLHL25, SYVN1, FBXL15, LNPEP, FBXL16, MARCH3, ITCH, UBE2T, TSPAN17, KBTBD2, FBXL3, TRIM32]
